Sanofi Pasteur has announced that the first lots of Fluzone (Influenza vaccine) for the 2014–2015 season have been shipped.

This shipment represents the first of more than 65 million doses of seasonal influenza vaccine the company plans to deliver in August. Shipment of Fluzone began on July 21, 2014 and direct shipments to health care providers and distributors will be ongoing through October.

RELATED: 2014 Vaccination Schedule: Adults

This season, Sanofi Pasteur will provide the following influenza vaccine options:

  • Fluzone vaccine is approved for use in people six months of age and older. Fluzone vaccine will be available in two presentations: a 0.5mL prefilled syringe and a 5mL multi-dose vial. Children 6–35 months of age should receive a 0.25mL dose; children ≥36 months of age, adolescents, and adults should receive a 0.5mL dose. Fluzone vaccine is the only trivalent influenza vaccine licensed by the FDA for children as young as six months of age.
  • Fluzone Quadrivalent vaccine, which helps protect against four influenza strains (two A strains and two B strains), was first licensed by the FDA in 2013. The influenza B strain is associated with high hospitalization and mortality rates, especially in children and young adults. In fact, on average, over multiple recent seasons, 34% of influenza-related deaths in children up to 18 years of age were due to influenza B. Like Sanofi Pasteur’s Fluzone vaccine, Fluzone Quadrivalent vaccine is licensed for use in children six months of age and older, adolescents, and adults.
  • Fluzone High-Dose vaccine, which was introduced in 2010, is available for adults ≥65 years of age. Adults age ≥65 years are at greater risk for influenza and its complications because the immune system weakens with age. Fluzone High-Dose vaccine contains four times the amount of antigen than is contained in standard-dose Fluzone vaccine and induces higher antibody responses against the flu to address the age-related decline of their immune system.
  • Fluzone Intradermal vaccine, which was introduced in 2011, will also be available for the upcoming influenza season. Fluzone Intradermal vaccine features a 90% smaller, affixed microneedle, and offers an efficient way to vaccinate patients by eliminating steps in the vaccination process.

Healthcare providers wishing to reserve vaccine can do so by calling 1-800-VACCINE (1-800-822-2463) or by visiting